Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC

June 11, 2022 updated by: Chen Xiaoping, Tongji Hospital

Efficacy and Safety of Immune Checkpoint Inhibitors (ICIs) and Tyrosine Kinase Inhibitors (TKIs) Therapy for Hepatocellular Carcinoma (HCC)：a Multicenter, Retrospective Study on the Real-world in China

China is a high-risk area of Hepatocellular Carcinoma (HCC). Although Chinese population accounts for 18.4% of the global population, the number of new HCC patients accounting for about half of the global, which seriously threatens the lives and health of the people. The investigators establish multi-center, retrospective research methods, collecting the data of HCC treatment with system treatment (ICIs and TKIs) plus or without local treatment in the last 3 years, comprehensive assessment of their efficacy and safety, explore whether the efficacy of system treatment combination local treatment showed better effect compared with system or local monotherapy. Our study will find a new way to improve the prognosis of HCC patients.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This was a multi-center, retrospective study involving 2000 patients with HCC receiving ICIs (Programmed cell death protein-1 (PD-1) or Programmed cell death ligand 1 (PDL-1)) and TKIs (Lenvatinib or Sorafenib), ICIs and TKIs plus local treatment (TAC, Hepatic artery infusion chemotherapy (HAIC), radiofrequency (RF) ablation, microwave ablation, radiotherapy, etc.), and local monotherapy between Jan, 2019 and Dec, 2021 in China. Efficacy was evaluated with objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), time to tumor progression (TTP), and 1year and 2 years overall survival (OS). Treatment-related adverse events (TRAEs) were recorded and graded. Efficacy and safety of three groups were compared. Stratified analysis was performed according to patients baseline characteristics and medication regimen for combination therapy.

Study Type

Observational

Enrollment (Anticipated)

2000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Xiaoping Chen
  • Phone Number: +862783663400
  • Email: chenxp@163.com

Study Locations

  • China
    • Hubei
      • Wuhan, Hubei, China, 430030
        • Recruiting
        • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Hepatocellular carcinoma patients using ICIs (PD-1 or PDL-1) therapy plus TKIs (Lenvatinib or sorafenib), ICIs plus TKIs with local therapy (TACE, HAIC, RF ablation, microwave ablation, etc), local therapy only

Description

Inclusion Criteria:

  • Clinical diagnosis of hepatocellular carcinoma
  • Treated with ICIs (PD-1 or PDL-1) therapy plus TKIs (Lenvatinib or sorafenib)
  • Treated with local therapy (TACE, HAIC, RF ablation, microwave ablation, radiotherapy, etc)
  • Treated Treated with ICIs plus TKIs and local therapy
  • Have complete medical record that can complete the OR or 1 year OS assessment and follow-up.

Exclusion Criteria:

  • Patients who do not have complete medical record and follow-up information after treatment；
  • The researchers have evidence that it is not suitable for this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Systemic therapy
ICIs (PD1 or PDL-1)+TKIs (Lenvatinib or Sorafenib)
Drug: Lenvatinib Oral Product
Lenvatinib or Sorafenib
Drug: PD-1 inhibitor
Programmed cell death protein-1 (PD-1) or Programmed cell death ligand 1 (PDL-1
Local treatment
local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.
Procedure: Local treatment
Local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.
Triple therapy

Systemic therapy plus Local treatment:

ICIs (PD1 or PDL-1)+TKIs (Lenvatinib or Sorafenib) plus local treatment (TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc)
Drug: Lenvatinib Oral Product
Lenvatinib or Sorafenib
Drug: PD-1 inhibitor
Programmed cell death protein-1 (PD-1) or Programmed cell death ligand 1 (PDL-1
Procedure: Local treatment
Local treatment include: TACE, HAIC, RF Ablation, Microwave Ablation, Radiotherapy, etc.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The objective response rate (ORR)
Time Frame: 8 weeks
ORR in three groups were compared
8 weeks
The overall survival (OS)
Time Frame: 12 months
1 year OS in three groups were compared
12 months
The treatment-related adverse events (TRAEs)
Time Frame: 12 months
Rate of participants with treatment-related adverse events as assessed by CTCAE v5.0
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The progression-free survival (PFS)
Time Frame: 8 weeks
ORR in three groups were compared
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Tongji Hospital

Investigators

  • Principal Investigator: Xiaoping Chen, Doctor, Tongji Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2021

Primary Completion (Anticipated)

August 30, 2022

Study Completion (Anticipated)

December 31, 2022

Study Registration Dates

First Submitted

May 26, 2022

First Submitted That Met QC Criteria

June 11, 2022

First Posted (Actual)

June 15, 2022

Study Record Updates

Last Update Posted (Actual)

June 15, 2022

Last Update Submitted That Met QC Criteria

June 11, 2022

Last Verified

June 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHL2022

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

We haven't decided whether it needs to cooperate with other PI.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe